These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19464128)

  • 1. Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?
    Damment SJ; Cox AG; Secker R
    Toxicol Lett; 2009 Aug; 188(3):223-9. PubMed ID: 19464128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic lanthanum is excreted in the bile of rats.
    Damment SJ; Pennick M
    Toxicol Lett; 2007 Jun; 171(1-2):69-77. PubMed ID: 17570622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
    Lacour B; Lucas A; Auchère D; Ruellan N; de Serre Patey NM; Drüeke TB
    Kidney Int; 2005 Mar; 67(3):1062-9. PubMed ID: 15698446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.
    Bronner F; Slepchenko BM; Pennick M; Damment SJ
    Clin Pharmacokinet; 2008; 47(8):543-52. PubMed ID: 18611063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
    Behets GJ; Verberckmoes SC; Oste L; Bervoets AR; Salomé M; Cox AG; Denton J; De Broe ME; D'Haese PC
    Kidney Int; 2005 May; 67(5):1830-6. PubMed ID: 15840030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats.
    Damment SJ; Shen V
    Clin Nephrol; 2005 Feb; 63(2):127-37. PubMed ID: 15730055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
    Damment SJ; Pennick M
    Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.
    Pennick M; Dennis K; Damment SJ
    J Clin Pharmacol; 2006 Jul; 46(7):738-46. PubMed ID: 16809799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
    Bervoets AR; Behets GJ; Schryvers D; Roels F; Yang Z; Verberckmoes SC; Damment SJ; Dauwe S; Mubiana VK; Blust R; De Broe ME; D'Haese PC
    Kidney Int; 2009 Feb; 75(4):389-98. PubMed ID: 19052535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanthanum: a safe phosphate binder.
    Persy VP; Behets GJ; Bervoets AR; De Broe ME; D'Haese PC
    Semin Dial; 2006; 19(3):195-9. PubMed ID: 16689967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
    J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
    Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F; Speake M; Hutchison AJ
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate: time to abandon prejudices?
    Brancaccio D; Cozzolino M
    Kidney Int; 2007 Feb; 71(3):190-2. PubMed ID: 17252028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption.
    Graff L; Burnel D
    Res Commun Mol Pathol Pharmacol; 1995 Sep; 89(3):373-88. PubMed ID: 8680806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lanthanum carbonate.
    Joy MS; Kshirsagar A; Candiani C; Brooks T; Hudson JQ
    Ann Pharmacother; 2006 Feb; 40(2):234-40. PubMed ID: 16449551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M
    Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.